Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting NCT07659574 Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting

NCT07659574
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 75 years old at the time of signing the consent form, of any gender.
  • People who have been diagnosed with type 2 diabetes for at least 3 months, based on 2019 World Health Organization criteria.
  • People who have been managing their diabetes through diet and exercise only, without any blood sugar-lowering medications, for at least 3 months before the screening visit.
  • People whose HbA1c (a measure of average blood sugar over time) is between 7.5% and 10.5% at the screening visit.
  • People with a body mass index (BMI) of 23.0 or higher at screening, whose body weight has been stable (changed less than 5%) in the 3 months before screening.
  • People (and their partners) who have no plans to become pregnant from screening until 6 months after the trial ends, who are willing to follow the contraceptive methods specified by the trial, and who have no plans to donate sperm or eggs within 6 months after the trial ends.
  • People who have been fully informed about the study and have voluntarily signed a written consent form.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a known allergy or sensitivity to the study drug, its ingredients, or similar medications.
  • People who, in the 3 months before screening, have used any blood sugar-lowering medications (including GLP-1 medications, metformin, sulfonylureas, DPP-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, glinides, SGLT-2 inhibitors, insulin except for short-term use of 14 days or less for acute situations, traditional Chinese medicines, or health supplements that lower blood sugar).
  • People who, in the 3 months before screening, have used medications that may affect blood sugar levels, such as steroid tablets or growth hormone, unless the total use was less than 7 days and the last dose was taken long enough ago (confirm with trial site).
  • People who, in the 3 months before screening, have used any weight-loss medications, including prescription or over-the-counter options such as orlistat or liraglutide.
  • People diagnosed with any type of diabetes other than type 2, such as type 1 diabetes or other specific forms of diabetes related to genetic conditions or pancreatic disease.
  • People with a history of acute or chronic pancreatitis, or who have had pancreatic surgery.
  • People with a history of symptomatic gallbladder disease in the year before screening (unless they had their gallbladder removed at least 3 months before screening with no lasting complications), or whose screening ultrasound shows large gallstones (2 cm or larger), gallbladder polyps (1 cm or larger), or other gallbladder conditions the study doctor considers a safety concern.
  • People with a personal or family history (in parents, children, or siblings) of a specific type of thyroid cancer called medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia type 2.
  • People with a history of blood disorders that may affect HbA1c test results or pose additional health risks, such as aplastic anemia, myelodysplastic syndromes, sickle cell disease, or thalassemia.
  • People with a history of moderate to severe depression or serious psychiatric conditions, including schizophrenia, bipolar disorder, or suicidal thoughts or attempts.
  • People who have had a significant heart or stroke-related event in the 6 months before screening.
  • People with serious eye conditions affecting the retina or macula (such as proliferative retinopathy, macular edema, or retinal detachment) that the study doctor determines require urgent treatment, either currently or in the past.
  • People who have had a severe low blood sugar episode (requiring help from another person to recover) or repeated low blood sugar symptoms (two or more episodes in 6 months) in the 6 months before screening.
  • People who have had serious diabetes-related emergencies such as diabetic ketoacidosis, hyperosmolar hyperglycemic state requiring hospitalisation, or diabetic foot in the 6 months before screening.
  • People with a history of any cancer (malignancy).
  • People who have lost 400 mL or more of blood (through injury, blood draws, or donation) in the 3 months before screening, or who have received a blood or blood product transfusion in that time.
  • Women who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Kids Helpline — 24/7, free and private for anyone aged 5 to 25: 1800 55 1800
  • headspace — mental health support for 12 to 25 year olds: headspace.org.au
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
10 August 2026
Est. completion
24 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov